Publications in collaboration with researchers from Complexo Hospitalario Universitario de Santiago (87)

2024

  1. Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial

    Digestive Diseases

  2. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease

    United European Gastroenterology Journal, Vol. 11, Núm. 1, pp. 9-18

2022

  1. Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 697-705

  2. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  3. Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

    Inflammatory bowel diseases

  4. Erratum: Re-induction with Intravenous Ustekinumab in Patients with Crohn's Disease and a Loss of Response to This Therapy (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab015)

    Inflammatory Bowel Diseases

  5. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  6. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  7. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  8. Mild to moderate ulcerative colitis: Call me by my name

    United European Gastroenterology Journal

  9. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  10. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  11. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy

    Inflammatory bowel diseases, Vol. 28, Núm. 1, pp. 41-47

  12. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  13. SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 10, pp. 737-741

  14. Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study

    Journal of Crohn's & colitis, Vol. 16, Núm. 9, pp. 1428-1435

  15. The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study

    Journal of Crohn's & colitis, Vol. 16, Núm. 11, pp. 1676-1686

  16. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

    Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83